CpG Oligodeoxynucleotides Induce VEGF Production for Neovascularization

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods lack effective agents to promote angiogenesis, a crucial process for wound healing and tumor growth, and there is a need to identify new angiogenic agents to address conditions like atherogenesis, arthritis, and diabetic retinopathy.

Innovation Solution

Administration of CpG oligodeoxynucleotides to induce the production of vascular endothelial growth factor (VEGF) and promote neovascularization by contacting cells with CpG oligonucleotides, thereby stimulating angiogenesis in targeted tissues.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If CpG oligodeoxynucleotides are administered to induce angiogenesis, then neovascularization is promoted, but the mechanism and specificity need to be better understood and controlled

Engineering Contradiction:

Improveangiogenesis promotionVSAvoidmechanism understanding

Core Design Contradiction:

ProductivityVSDifficulty of detecting and measuring

Solution Approach 1:

The patent identifies VEGF (vascular endothelial growth factor) as the intermediary mediator through which CpG oligodeoxynucleotides exert their angiogenic effect. By demonstrating that CpG ODNs stimulate VEGF production by cells, the patent clarifies the mechanism of action, allowing for better control and understanding of the angiogenesis promotion process.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Productivity

If CpG oligodeoxynucleotides are used to induce angiogenesis, then new blood vessels form, but off-target effects and safety need to be managed

Engineering Contradiction:

Improveneovascularization inductionVSAvoidoff-target effects

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent employs anti-VEGF antibodies as a feedback mechanism to inhibit and control the angiogenic response. By demonstrating that anti-VEGF antibodies can block the angiogenic effect of CpG ODNs, the patent provides a means to manage off-target effects and control the magnitude of neovascularization induction, thereby improving safety.

Inventive Principle:

Principle #23Feedback

3Productivity

If CpG oligodeoxynucleotides are administered, then angiogenesis is stimulated, but the dosage and optimal conditions need optimization

Engineering Contradiction:

Improveangiogenesis stimulationVSAvoiddosage optimization

Core Design Contradiction:

ProductivityVSAdaptability or versatility

Solution Approach 1:

The patent systematically varies parameters such as CpG ODN dosage, sequence composition, and delivery conditions to optimize angiogenesis stimulation. By establishing dose-response relationships and identifying optimal parameters, the patent enables adaptable application across different therapeutic scenarios while maintaining safety and efficacy.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS7615227B2Use of CpG oligodeoxynucleotides to induce angiogenesis

Publication Date: 2009.11.10 GOVERNMENT OF THE UNITES STATES OF AMERICA AS REPRESENTED BY THE SEC OF THE DEPT OF HEALTH & HUMAN SERVICES THE

AI summary

This disclosure provides a method of inducing production of vascular endothelial growth factor by a cell. The method includes contacting the cell with a CpG oligonucleotide, thereby inducing the production of vascular endothelial growth factor by the cell. The disclosure further provides a method inducing neovascularization in a tissue. This method includes comprising introducing a CpG oligodeoxynucleotide into an area of the tissue wherein the formation of new blood vessels is desired, thereby inducing neovascularization in the area of the tissue.